Please assess the completion status of the following clinical trial:

Trial Title: A Study of MK-7145 in Participants With Renal Insufficiency (Part I) and Heart Failure With Renal Insufficiency (Part II) (MK-7145-011)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~Parts I and II~* If female, must be of non-child bearing potential or, if of child-bearing potential agrees to use at least 2 acceptable contraceptive measures~* Body Mass Index (BMI) \>=17.5 and \<=38 kg/m\^2~* No present history of clinically significant uncontrolled arrhythmias on electrocardiogram (ECG)~* Nonsmoker or a light smoker consuming up to an average of 20 cigarettes (or equivalent tobacco product) per day.~Part I Only~- Estimated creatinine clearance of ≤45 mL/min.~Part II Only~* Class II or III heart failure as specified by the New York Heart Association (NYHA) functional classification for heart failure with NT-proBNP \>=1000 pg/mL on clinically optimized therapy with a stable dose (for at least 2 weeks) of furosemide or torsemide~* Estimated creatinine clearance of ≤45 mL/min~Exclusion Criteria:~Parts I and II~* Mentally or legally institutionalized and/or incapacitated, has significant emotional problems or has a history of a clinically significant psychiatric disorder over the last 5 years. This includes any mood disorder requiring concomitant use of lithium~* Diagnosed with acute coronary syndrome or acute cardiovascular (CV) event, or has been hospitalized for HF exacerbation within less than 3 months of study entry~* Unstable angina pectoris~* Diabetes requiring high dose peroxisome proliferator-activated receptor (PPAR) antagonist (e.g. \>30 mg of pioglitazone) or unstable insulin use~* Infectious disease requiring concomitant use of aminoglycosides~* Low plasma potassium (hypokalemia)~* Recent (within 6 months) history of stroke, uncontrolled seizures, or uncontrolled major neurological disorder~* Urinary retention, hydronephrosis or hydroureter~* Active nephrocalcinosis, nephrolithiasis, or hypercalciuria~* Functional disability that can interfere with rising from a semi-recumbent position to the standing position~* History of malignant neoplastic disease~* Unable to refrain from the use of medication, including prescription and non-prescription drugs such as high-dose aspirin (≥325 mg/day), non-steroidal anti-inflammatory drugs (NSAIDs), human immunodeficiency virus (HIV) protease inhibitors (ritonavir, indinavir, nelfinavir), macrolide antibiotics (erythromycin, telithromycin, clarithromycin), chloramphenicol, azole antifungals (fluconazole, ketoconazole, itraconazole, nefazodone, aprepitant, verapamil, diltiazem, etc.), anticonvulsants and mood stabilizers (e.g., phenytoin, carbamazepine, oxcarbazepine), barbiturates (phenobarbital), HIV non-nucleoside reverse transcriptase inhibitors (efavirenz, nevirapine, etravirine), rifampicin, modafinil, St John's wort, cyproterone (antiandrogen, progestin), etc. beginning approximately 2 weeks (or 5 half-lives), prior to administration of the initial dose of study drug, throughout the study (including washout intervals between treatment periods) until the poststudy visit~* Consumes excessive amounts of alcohol, defined as greater than 5 glasses of alcoholic beverages (1 glass is approximately equivalent to: beer \[284 mL/10 ounces\], wine \[125 mL/4 ounces\], or distilled spirits \[25 mL/1 ounce\]) per day~* Consumes excessive amounts, defined as greater than 6 servings (1 serving is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, or other caffeinated beverages per day~* Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) or participated in another investigational study within 4 weeks~* Regular user of any illicit drugs or has a history of drug (including alcohol) abuse within approximately 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- MK-7145 8 mg (Part I:Period 1) (Type: EXPERIMENTAL): Single daily dose of 8 mg MK-7145 for 5 days, capsules, orally administered in a fasted state
- Furosemide 40 mg (Part I:Period 2) (Type: ACTIVE_COMPARATOR): Two daily doses of one 40 mg Furosemide tablet for 5 days administered in a fasted state
- MK-7145 16 mg (Part I:Period 3) (Type: EXPERIMENTAL): Single daily dose of 16 mg MK-7145 for 5 days, capsules, orally administered in a fasted state
- Furosemide/Torsemide Run-in (Part II:Period1) (Type: ACTIVE_COMPARATOR): Run-in of stable, clinically optimized maintenance dose regimen of furosemide or torsemide for at least 2 weeks
- MK-7145 10 mg (Part II:Period 2) (Type: EXPERIMENTAL): Single daily dose of 10 mg MK-7145 for 14 days, capsules, orally administered in a fasted state
- MK-7145 16 mg (Part II:Period 3) (Type: EXPERIMENTAL): Single daily dose of 16 mg MK-7145 for 14 days, capsules, orally administered in a fasted state
- MK-7145 24 mg (Part II:Period 4) (Type: EXPERIMENTAL): Single dose of 24 mg MK-7145 for 28 days, capsules, orally administered in a fasted state

Based on this trial design, predict the completion outcome and termination type (if applicable).